• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Avail Scientific Signs LOI to Acquire Florida Neurological Testing Company Relai Neuro

Share:

January 24, 2023

TORONTO, ON / ACCESSWIRE / January 19, 2023 / AVAIL SCIENTIFIC (OTC PINK:MOBO) is pleased to announce it is entering into a letter of intent (LOI) to acquire Florida based Relai Neuro LLC which provides Neurological testing and data management.

This acquisition will allow Relai to double its sales force over the next three months as well as expand services into California, Texas, and Colorado.

Dr. James Thompson, CEO of Relai Neuro, says; “We are excited to work with Avail Scientific. The acquisition will allow us to bolster our offerings and our team. Additionally, the acquisition of Relai will allow us to achieve our goals of expansion in Florida, as well as expand quickly into California, Texas, and Colorado markets.”

“Relai Nero allows Avail to continue to accelerate our treatment applications, testing and supporting data collection as we strive to become a world leader in the clinically studied and supported use of psychedelic therapeutics for treatment of addiction & mental health issues,” says Avail CEO, Michael Paul.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Relai Neuro provides neurological testing and data management to rehab and mental health treatment centres in Florida.

Relai’s products and methodology allow for the direct measurement of progress in neural functions of patients under various treatments. For example, Relai is currently measuring the effects of Psilocybin micro-dosing on addiction in patients within a clinical environment.

RelaiNeuro – https://nusqu.com/relaineuro

About Avail Scientific

Avail Scientific is working to facilitate a medical and social revolution of the current pharmacological therapies for addiction and the underlying causes by providing evidence-based diagnostic and data acquisition programs. These substances can be used as both treatment for addiction and as preventative therapy by addressing the health challenges underlying substance abuse.

We are building a platform to both educate and equip healthcare professionals with the data to use these therapeutic tools efficiently. Our objective is to treat this medical condition and prove out rehabilitation and preventative therapy programs with our partners in healthcare communities, both local and globally.

Avail Scientific is positioned to become a global leader in eliminating the needless suffering that surrounds addiction and mental health issues by providing effective data and patient monitoring to validate their efficacy.

Source: Bio Space

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • InnoCare and ArriVent Announce Clinical Development CollaboratioInnoCare and ArriVent Announce Clinical Development Collaboratio
  • Private equity-backed M&A in China stalls as investors put off deals amid trade warPrivate equity-backed M&A in China stalls as investors put off deals amid trade war
  • Acerus Announces Closing of Acquisition of Serenity Pharmaceuticals LLC and Acquisition of Global Rights to Noctiva™Conference Call to be Held on March 9, 2022 at 8:30am ET to Discuss TransactionAcerus Announces Closing of Acquisition of Serenity Pharmaceuticals LLC and Acquisition of Global Rights to Noctiva™Conference Call to be Held on March 9, 2022 at 8:30am ET to Discuss Transaction
  • Bitbiome has Raised 700 Million Jpy in Series B FinancingBitbiome has Raised 700 Million Jpy in Series B Financing
  • CareAbout Health Selects Innovaccer to Scale VBC for Expanding Provider NetworkCareAbout Health Selects Innovaccer to Scale VBC for Expanding Provider Network
  • AngioDynamics to Acquire RadiaDyne and its Revolutionary OARtrac® Radiation Dose Monitoring Platform to Further Expand Oncology PortfolioAngioDynamics to Acquire RadiaDyne and its Revolutionary OARtrac® Radiation Dose Monitoring Platform to Further Expand Oncology Portfolio
  • Telehealth and COVID-19: Overcoming New Challenges for Providers and PayersTelehealth and COVID-19: Overcoming New Challenges for Providers and Payers
  • Plandai Biotechnologies, Inc. Announces Termination of Asset Acquisition Agreement with EV Hotel, Updates on Status of Independent AuditPlandai Biotechnologies, Inc. Announces Termination of Asset Acquisition Agreement with EV Hotel, Updates on Status of Independent Audit

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications